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Aberrant Wnt signaling can drive cancer development. In many cancer types, the genetic basis of 
Wnt pathway activation remains incompletely understood. Here, we report recurrent somatic 
mutations of the Drosophila tumor suppressor-related gene FAT1 in glioblastoma (20.5%), 
colorectal cancer (7.7%), and head and neck cancer (6.7%). FAT1 encodes a cadherin-like protein, 
which we found is able to potently suppress cancer cell growth in vitro and in vivo, by normally 
binding β-catenin and antagonizing its nuclear localization. Inactivation of FAT1 via mutation 
therefore promotes Wnt signaling and tumorigenesis, and impacts patient survival. Together, these 
data strongly point to FAT1 as a tumor suppressor gene driving loss of chromosome 4q35, a 
prevalent region of deletion in cancer. Loss of FAT1 function is a frequent event during 
oncogenesis. These findings unify two outstanding questions in cancer biology: the basis of Wnt 
activation in non-colorectal tumors, and the identity of a 4q35 tumor suppressor.
Chromosome 4q35 is frequently lost in numerous types of human cancer, and it has been 
hypothesized that this region contains a tumor suppressor gene1-6. We have identified 
frequent somatic mutations in the FAT1 gene, located on 4q35.2. FAT1 encodes a member 
of the FAT protocadherin family, a group of transmembrane proteins commonly expressed 
in epithelial tissues. The functions of protocadherin proteins remain incompletely 
understood.
In mammals, this protein family includes FAT1, FAT2, FAT3 and FAT4, all related to the 
Drosophila tumor suppressor Fat, which is known to play an important role in key 
developmental processes7-9. In Drosophila, loss of Fat leads to cell cycle dysregulation and 
hyperproliferation of larval imaginal discs9-12. Fat exhibits closest homology with 
mammalian FAT4, which has been implicated in both planar cell polarity and Hippo 
signaling13-17. In contrast, FAT1 is not thought to play a strong role in these 
processes 9,18-21. In human cells, FAT1 is localized to the cell membrane, often concentrated 
at filopodia, lamellipodia, and sites of cell-cell contact. Although FAT1 has been shown to 
regulate cell-cell association and actin dynamics10, the role of this protein in cancer has been 
unknown.
Aberrant activation of the Wnt/β-catenin pathway drives the development of many types of 
human malignancy 22-26. In certain cancers including colorectal carcinoma, this activation is 
frequently due to alteration of Wnt pathway genes, commonly APC or CTNNB1 
mutation 27-31. However, the genetic basis of Wnt pathway activation in other cancer types 
is not well understood. Cadherin-related proteins can interact with β-catenin and sequester it 
at the cell periphery, thereby regulating its transcriptional activity32-36. If not sequestered at 
the cell membrane, β–catenin binds to the T-cell factor (TCF) proteins, which translocate to 
the nucleus and activate Wnt target genes22,37, promoting cell proliferation, tumor growth, 
and stem cell identity22,24,36,38. Here, we present genetic, functional, and mechanistic data 
that identify the protocadherin FAT1 gene on 4q35 as a tumor suppressor that, when 
inactivated, leads to aberrant Wnt/β-catenin signaling in multiple types of cancer.
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Results
Deletion at 4q35 in multiple cancer types
The broad nature of copy number loss on chromosome 4q35 has made identification of the 
driving gene(s)in this region difficult. To identify candidates for tumor suppressor genes on 
chromosome 4q35, we began by examining this region using an array comparative genomic 
hybridization dataset from 3,131 cancer samples (Tumorscape dataset)39. In this large 
collection of copy number profiles, deletions on chromosome 4q35 containing FAT1 were 
frequent (834 tumors; 26.6%) and observed in 8 of 14 cancer types, including central 
nervous system, colorectal, ovarian, and squamous cell cancers (Fig. 1a, Supplementary Fig. 
1a, and Supplementary Table 1). Pooling data across all samples, the smallest observed 
region of deletion encompassed 14 genes (q=5.1×10-56), none of which corresponded to 
genes definitively known to play a functional role in cancer (Supplementary Table 2). FAT1 
was intriguing given its homology to the Drosophila Fat tumor suppressor gene. We 
therefore examined the candidate gene FAT1 further, by assaying copy number in 42 
glioblastoma multiforme (GBM) tumor samples using quantitative polymerase chain 
reaction, and found a high rate of homozygous deletion (24 of 42, 57.1%) (Fig. 1b). This 
was a higher rate of deletion than found in brain tumors in the Tumorscape dataset (∼15%), 
possibly due to differences in the representation of glioblastoma subtypes, or due to other 
unknown clinicopathologic differences, in each cohort. Further study will be needed to 
examine the prevalence of FAT1 deletion across different glioma subsets.
Somatic mutations in FAT1 across multiple cancer types
Next, to determine whether somatic mutations occurred in any of the genes within the 14 
gene deleted region, we sequenced the genes in human tumors and matching normal tissue: 
39 GBM, 39 colon, and 60 head and neck squamous cell carcinomas (gene set listed in 
Supplementary Table 2). We used Sanger sequencing to sequence all exonic regions. Single 
nucleotide polymorphisms (SNPs) were filtered out first using dbSNP40, and also by 
comparing sequencing data from the matched normal DNA. We identified non-synonymous 
somatic mutations across multiple types of human malignancies in only the FAT1 gene 
(Supplementary Figure 1b). We identified and verified (via re-sequencing) 17 mutations in 
FAT1 in glioblastoma multiforme (8 of 39; 20.5%), colon cancer (3 of 39; 7.7%), and head 
and neck squamous cell cancer (4 of 60; 6.7%) (Fig. 1c and Table 1). The ratio of non-
synonymous to synonymous mutations was 3.5:1, consistent with the positive selection that 
driver mutations typically undergo. Nearly all mutations were located in known functional 
domains within the predicted protein product. As shown in Fig. 1c, the observed FAT1 
missense mutations occurred mainly in the cadherin domains and the intracytoplasmic 
domain. The frequency and location of alterations in FAT1 suggest that these cancer-
associated mutations may have functional consequences. Importantly, 3 mutations (18%) 
were truncating (stop codon or frameshift) and a number were homozygous, a mutation 
pattern frequently observed in bona fide tumor suppressor genes. An analysis of the 
missense mutations with Polyphen-2 revealed that many (9 of 15, 60%) were predicted to 
have damaging effects on protein function (Supplementary Table 3)41. These genetic data 
strongly suggest that FAT1 encodes a tumor suppressor that helps drive loss of chromosome 
4q35, although we cannot rule out the presence of another tumor suppressor in the region.
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Functional validation of FAT1 as a tumor suppressor gene
How does FAT1 function as a tumor suppressor? To answer this, we first sought to 
determine if FAT1 possesses growth-suppressive properties in human cancer cells. FAT1 
protein expression and mutational status were determined in several cell lines, including 
glioma and immortalized primary human astrocyte cells42,43 (Supplementary Fig. 2a; 
Supplementary Table 4). We cloned the cDNA for FAT1 and 3 FAT1 mutations observed in 
tumors (Pro4309Ala, Ala4419Ser, and Thr4511Ile). FAT1 is a large gene and in its full 
form, it is not amenable to manipulation. In order to work with it, as is commonly done, we 
constructed a shortened cDNA cassette (truncated FAT1, annotated as FAT1_Trunc) that 
was amenable to experimental manipulation but retained all key functional domains, 
including the N-terminus, first 2 cadherin domains, all 5 EGF repeats, the transmembrane 
region and the cytoplasmic domain. A FLAG tag was added at the 3′ end. Transfection of all 
cDNA constructs produced the predicted protein product (Supplementary Fig. 2b). We then 
examined the functional consequences of introducing FAT1 into human GBM cell lines. 
Using a colony formation assay, we observed a consistent suppression of colony formation 
following FAT1_Trunc expression in glioma cells (Fig. 1d). Fluorescence-activated cell 
sorting (FACS) analysis revealed that FAT1 inhibited cell cycle progression at the G1-S 
checkpoint, significantly reducing the proportion of cells in S phase, and increasing the 
proportion of cells in G1 phase. Introduction of FAT1 also significantly lowered the 
frequency of BrdU incorporation in all cells tested, indicating a reduction in the proportion 
of cells actively synthesizing DNA (Fig. 1e).
To further test the effects of mutations on the growth suppressive properties of FAT1, we 
established a GBM cell line that stably expressed FAT1_Trunc and the 3 cancer-derived 
cytoplasmic mutations. Expression of non-mutated FAT1significantly suppressed the rate of 
cell growth, an effect abrogated by all 3 mutations (Fig. 2a). Concordant results were seen in 
a soft-agar assay measuring anchorage-independent growth, where growth suppression was 
seen with FAT1_Trunc, but not mutated FAT1 (Fig. 2b). Cell cycle analyses and BrdU 
assays confirmed that the anti-proliferative properties of FAT1 were significantly 
diminished by the mutations (Figs. 2c and 2d). To determine the effects of non-mutated and 
mutated FAT1 on tumorigenesis in vivo, we used a murine xenograft assay. Following 
subcutaneous injection of cells stably expressing non-mutated FAT1_Trunc, mutated 
FAT1_Trunc, or neither (empty vector), we measured the incidence and growth rate of 
xenograft tumors. FAT1_Trunc dramatically reduced both the incidence and size of tumors 
while all three FAT1 mutants did not exhibit any significant tumor-suppressive effect (Figs. 
2e and 2f). Pathologic analysis of xenograft tumor tissue confirmed a marked suppression of 
cellular proliferation in non-mutated FAT1 tumors, but not in FAT1-mutated tumors, 
compared to empty vector, as measured by Ki-67 staining (Fig. 2g).
To determine whether inactivation of FAT1 directly modulates cancer cell growth, we 
knocked down FAT1 using two independent short interfering RNAs (siRNA). We used 
glioma cell lines, and also examined the effects of FAT1 depletion in a non-cancer cell line 
– immortalized human astrocytes (Fig. 3a). The immortalized astrocytes were derived from 
primary astrocytes transfected with hTERT, E6, and E7, and are a well-characterized human 
astrocyte model system42. In glioma cells and immortalized astrocytes with endogenous 
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expression of FAT1, knockdown with FAT1 siRNA, but not scrambled-sequence (non-
targeted) siRNA, led to an increase in cell growth (Fig. 3b), cell cycle progression (Fig. 3c), 
and BrdU incorporation (Fig. 3d).
We then asked whether depletion of endogenous FAT1 could be rescued with 
overexpression of the FAT1_Trunc construct (Fig. 3e). FAT1 depletion with siRNA led to 
accelerated cell growth, an effect which was repressed by concurrent transient transfection 
of FAT1_Trunc (Fig. 3f). Cell growth was measured at sparse density in real time using a 
well-described system44,45 (xCELLigence, Roche). Similarly, the increase in BrdU staining 
seen after FAT1 knockdown, was reversed by concurrent FAT1_Trunc transfection (Fig. 
3g). The level at which the FAT1 knockdown phenotype was reversed was on par with the 
levels of FAT1_Trunc protein able to be achieved with transfection.
Together with our genetic observations, these functional data indicate that FAT1 acts as a 
tumor suppressor in human cancers, that loss of FAT1 promotes tumor growth, and that 
FAT1 mutations observed in cancer abrogate the tumor suppressive effects of FAT1.
Role of FAT1 in Wnt/β-catenin signaling
How does FAT1 suppress tumorigenesis at the molecular level, and how do mutations 
disrupt this ability? FAT4, rather than FAT1, is strongly associated with Hippo signaling in 
mammals8,17,20. There is some indication that, in the setting of endothelial injury repair, 
mammalian FAT1 can bind β–catenin. The details of this relationship, and the significance 
of this interaction in human cancers, are unknown35. Using immunoprecipitation, we found 
that endogenous FAT1 binds to β-catenin, and vice versa, in 293T cells and U251 glioma 
cells (Fig. 4a). Similarly, the FAT1_Trunc protein, when expressed in these cells, also binds 
β-catenin (Fig. 4b).
We then hypothesized that mutation or loss of FAT1 in cancer might lead to dysregulated 
Wnt signaling by abrogating proper FAT1/β-catenin interactions. Of note, 3 of 4 observed 
intracytoplasmic FAT1 mutations occurred directly in the putative β-catenin binding regions 
(Fig. 1d) 46. Using immunoprecipitation, we found that the cancer-derived cytoplasmic 
mutations in FAT1 exhibit a diminished ability to bind β-catenin (Fig. 4c). We therefore 
examined the consequences of FAT1 loss on β-catenin localization, in glioma cells and 
immortalized human astrocytes. Knockdown of FAT1 led to decreased β-catenin staining at 
the plasma membrane, and significantly increased β-catenin translocation to the nuclear and 
peri-nuclear regions, in both glioma cells and immortalized astrocytes (Fig. 4d). The shift in 
nuclear translocation was significant but not complete, likely owing to other regulators of β-
catenin (Fig. 4e).
Abnormal activation of the Wnt pathway is well-described in a number of human cancers as 
a promoter of cancer cell growth and tumorigenesis23. In order to confirm that the growth 
suppressive and anti-proliferative effects of FAT1 were mediated by inhibition of β-catenin 
transcriptional activity, we used a well-established luciferase reporter assay for β-catenin 
mediated transcription30. This assay uses a plasmid with TCF/LEF binding sites in the 
promoter region, driving expression of luciferase. Transfection of FAT1 significantly 
decreased β-catenin-mediated transcription, but this effect was abrogated by FAT1 mutant 
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constructs (Fig. 4f). Transfection of the constitutively active β-catenin S33Y mutant, which 
is resistant to phosphorylation and ubiquitylation30,47, upregulated β-catenin-mediated 
transcription to a substantially greater extent than wild-type β-catenin, but this effect was 
also repressed by co-transfection with FAT1 (Fig. 4g). Together, these data show that wild-
type FAT1 can potently antagonize β-catenin-mediated transcription, and that FAT1 
mutations found in cancer diminish this ability.
We examined the FAT1/β-catenin relationship further by co-transfecting FAT1_Trunc and 
β-catenin in cells, and determined the resultant effects on cell growth (Fig. 5a). Over-
expression of β-catenin accelerated cell growth, cell cycle progression, and increased BrdU 
incorporation, effects which were all repressed by co-transfection of FAT1_Trunc (Figs.5b 
and 5c). We then co-transfected siRNAs targeting FAT1 and β-catenin, in glioma cells that 
express both proteins (Fig. 5d). Knockdown of β-catenin in GBM cells reduced cell growth, 
cell cycle progression, and decreased BrdU incorporation, effects which were largely 
reversed by concomitant knockdown of FAT1 (Figs.5e and 5f; distinct siRNAs used in 
Supplementary Fig. 3).
Is FAT1 inactivation sufficient to activate Wnt signaling in cells? To answer this question, 
we knocked down FAT1 using 2 siRNAs, in glioma cells and immortalized human 
astrocytes. This significantly increased β-catenin-mediated transcription (Fig. 6a). We then 
examined multiple Wnt/β-catenin downstream targets in both glioma cells and immortalized 
astrocytes. We found that FAT1 knockdown led to consistent upregulation of multiple 
Wnt/β-catenin targets, including c-myc, cyclin D1, Id2, ITF2, claudin and TCF848-54 (Fig. 
6b). We did observe some variability between cell lines, in the degree of upregulation, likely 
due to the complexity of the network of upstream effectors.
To study global changes in the transcriptome resulting from FAT1 depletion, we knocked 
down FAT1 in immortalized astrocytes and two glioma cell lines. Knockdown was 
performed using 2 siRNAs, resulting in FAT1 downregulation (log2 fold change) of 3.74 
(siRNA#1) and 3.98 (siRNA#2). Gene expression was examined with the Affymetrix 
Human Genome U133A 2.0 microarray. We identified 1539 genes differentially expressed 
with both siRNAs, across all 3 cell lines (Supplementary Table 5), to determine biological 
pathways that are altered after FAT1 knockdown. We observed consistent enrichment of the 
Wnt/β-catenin signaling pathway across 4 independent pathway analysis modules: Ingenuity 
Pathway Analysis (p=.069), Biocarta (p=.040), Kyoto Encyclopedia of Genes and Genomes 
(p=.068), and Reactome (p=.005) (Fig. 6c and Supplementary Table 6). This demonstrates 
that FAT1 depletion shifts gene expression, affecting expression of Wnt/β-catenin pathway 
components.
FAT1 knockdown did not lead to enrichment of Hippo pathway signaling, or upregulation of 
downstream Hippo/YAP targets, such as CCNE1, CTGF, GLI2, FGF1, or AREG55-58. These 
findings are consistent with the described role of mammalian FAT4 (rather than FAT1) in 
Hippo signaling.
We then sought to validate these experimental findings in human tumors, by analyzing a 
dataset of 404 GBM samples from The Cancer Genome Atlas5. Comparing GBMs with low 
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FAT1 expression to GBMs with normal FAT1 expression, we identified 1035 genes 
differentially expressed (q<.05 and absolute log2 fold change > 1.2). In GBMs with low 
FAT1 expression, the Wnt/β-catenin signaling pathway was significantly enriched (p=.002) 
(Fig. 6d and Supplementary Table 7). Of the 4 mRNA expression defined GBM subtypes59, 
low FAT1 expression was most prevalent in the neural and mesenchymal categories, and 
was less common among GBMs in the classical category (p=.0033) (Fig. 6e). To determine 
whether the Wnt pathway genes are regulated by FAT1 in another cancer type, we 
performed a similar analysis in a large ovarian cancer dataset60, and again found that low 
FAT1-expressing tumors had significant Wnt/β-catenin pathway enrichment (p=.0038) (Fig. 
6f), based on 189 significantly differentially expressed genes (Supplementary Table 8). 
Together, analysis of these 2 datasets in different cancer types confirmed our experimental 
findings implicating a central role for FAT1 in modulation of Wnt/β-catenin pathway genes. 
Interestingly, in both a glioma dataset (Rembrandt dataset) and an ovarian cancer dataset 
(TCGA) containing clinical outcome data60, patients with low FAT1-expressing tumors 
experienced significantly longer survival (glioma: hazard ratio=.64, p=.037; ovarian cancer: 
hazard ratio=.61, p=.010) (Fig. 6g). The ovarian cancer dataset also included copy number 
and mutational data. Patients with tumors harboring mutation or homozygous deletion of 
FAT1 experienced significantly longer survival (hazard ratio=.46, p=.016) (Supplementary 
Fig. 4).
Activation of Wnt/β-catenin signaling is found in the vast majority of colorectal cancers, 
usually due to mutations in the genes APC, TCF4, AXIN2, and CTNNB1. We found FAT1 
mutations in 3 of 39 (7.7%) colon cancers. We examined the relationship between FAT1 
mutation and mutation of other commonly mutated Wnt pathway genes. Interestingly, 2 of 
the 3 FAT1-mutant tumors lacked mutations in APC, AXIN1, AXIN2, CTNNB1, and TCF4 
(Supplementary Fig. 5).
Cadherins also play a role in regulating cellular adhesion. For example, E-cadherin, a tumor 
suppressor, is able to bind and sequester β-catenin as well as control cell adhesion, 
establishing a mechanistic link between cell-cell contact and Wnt signaling 47,61,62. 
Knockdown of FAT1 alone in GBM cells was sufficient to cause a significant loss of cell-
cell adhesion (Supplementary Fig. 6). In order to determine whether the growth suppressive 
phenotype of FAT1 was attributable to tighter cell adhesion, we generated a non-adhesive 
FAT1 chimera by fusing the inert extracellular and transmembrane domains of the IL2R 
protein to the intracytoplasmic tail of FAT1 (“IL2R-FAT1_IC”), as has been done with 
various cadherin proteins32,63-66. In so doing, we sought to gauge the effects of the 
intracellular portion of the protein. We expressed both FAT1_Trunc and IL2R-FAT_IC in 
glioma cells, and confirmed that FAT1_Trunc, but not IL2R or IL2R-FAT1_IC, increased 
cell-cell adhesion (Supplementary Fig. 7). Similar to FAT1_Trunc, the non-adhesive IL2R-
FAT_IC protein also significantly suppressed glioma cell growth, BrdU incorporation, and 
cell cycle progression (Supplementary Fig. 8). These results demonstrate that the 
intracytoplasmic, β-catenin binding domain of FAT1, is sufficient to suppress cancer cell 
growth, in an adhesion-independent manner.
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Discussion
Our finding of FAT1 mutations in multiple cancer types suggests that FAT1 is a major cause 
of Wnt pathway activation in several human cancers in which the genetic alterations 
underlying Wnt activation are poorly defined. The core components of the Wnt pathway 
(e.g. APC, CTNNB1, AXIN1, AXIN2) are not mutated in GBM, ovarian, head and neck, 
breast, gastric, or many other cancers with aberrant Wnt activation5,60,67-69. The genetic, 
functional, and mechanistic data presented here demonstrate that FAT1 is a bona fide tumor 
suppressor that is inactivated and mutated in GBM, head and neck, and colon cancers.
While the primary genetic alterations causing Wnt activation in colon cancer are known, the 
widespread dysregulation of Wnt signaling in human malignancies such as ovarian, 
pancreatic and brain cancers, remains poorly understood70,71. In these cancer types, Wnt 
activation may in part be promoted by epigenetic events such as methylation of genes in the 
SFRP family, DKK family, or WIF-1. In cancer, these events may not be mutually exclusive 
with mutations in Wnt pathway genes, likely because these epigenetic events act in concert 
with mutations to establish “addiction” to Wnt signaling72-78. It would be of interest to 
examine the concordance of these alterations with FAT1 mutations in future studies.
We found FAT1 mutations in GBM, a finding that had not been detected in previous reports 
on GBM described by The Cancer Genome Atlas and Parsons et al., because the former 
study did not sequence this gene, and the latter study had limited statistical power due to the 
small number of tumors in the discovery set5,79,80. Recent genome-wide mutation surveys of 
pancreatic, head and neck, and ovarian cancers have observed some mutations in other 
members of the FAT family60,69,81. However, these mutations have occurred at lower 
prevalence, and no functional data have been reported. Indeed, prior to our studies, the 
biological significance of FAT1 inactivation in human cancers had not been elucidated.
Our genetic and functional data, together with these recent findings, strongly suggests that 
the members of the FAT family of genes are important players in cancer development. 
These findings implicate FAT1 mutations as a cause of Wnt pathway dysregulation in 
multiple cancer types.
In summary, our findings strongly support the idea that FAT1 is a frequent target of the 
chromosomal loss events on chromosome 4q35 seen in a wide range of human cancers. 
Inactivated FAT1 is unable to sequester β-catenin at the cell membrane, and thereby 
promotes Wnt signaling and tumor growth. We believe our findings have significant 
implications for our understanding of molecular events shaping oncogenesis and for 
elucidating the genetic drivers of Wnt activation.
Methods
Tumor samples
Glioblastoma (n=39), colorectal carcinoma (n=39), and head and neck squamous cell 
carcinoma (HNSCC, n=60) samples were obtained at the time of surgery at Memorial Sloan-
Kettering Cancer Center and University of California, Los Angeles, and snap frozen in 
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liquid nitrogen. Matched normal tissue or peripheral blood was also obtained for each 
patient. All patients provided informed consent as part of institutional review board-
approved protocols at MSKCC and UCLA. After pathologist confirmation of histology, 
source DNA was extracted. The glioblastoma patients had not received prior treatment with 
temozolomide82,83. Samples were fingerprinting with a 44 single nucleotide polymorphism 
panel on the Sequenom platform to confirm that tumor and normal DNA were correctly 
matched84.
Copy number analysis, expression analysis, and bioinformatics
Copy number data were analyzed using array CGH data from the Tumorscape dataset39. 
Copy number alterations were assigned using GISTIC, significance determined with false 
discovery rate-adjusted q values85, and data manually visualized with the Integrative 
Genomics Viewer.
FAT1 copy number was assessed in frozen GBM samples included in mutational analysis, 
and an additional 3 samples for which there was insufficient material for sequencing. Copy 
number was determined using genomic quantitative PCR (Taqman, Applied Biosystems) in 
triplicate. Pre-validated primers for FAT1 were obtained from Applied Biosystems 
(accession numbers HS00869981_cn, HS00703603_cn, HS01357303_cn). Reference human 
genomic DNA (Roche Applied Science, #11691112001) was used as reference and RNase P 
(Life Technologies, #4403328) as a diploid control86. Inferred copy number of <0.3 was 
considered a homozygous deletion.
Gene expression analysis in cell lines was performed with the Human Genome U133A 2.0 
microarray (Affymetrix). CEL files were imported into Partek Genomics Suite software 
(Partek, Inc) and normalized using RMA quartile normalization and log probe 
summarization. Differentially expressed genes were identified by assembling a list of genes 
that were differentially expressed across all 3 cell lines, comparing scrambled siRNA with 
each of two FAT1 siRNAs, at p<.05 (analysis of variance). This generated a list of 1539 
differentially expressed genes, corresponding to 2031 probes, after excluding six probes 
(0.3%) with inconsistent directionality between the 2 siRNAs (Supplementary Table 5). 
Enriched pathways were identified in the differentially expressed genes, in Ingenuity 
Pathway Analysis (Ingenuity Systems) and the Biocarta, KEGG and Reactome modules87. 
Ingenuity incorporates directional fold change, and a threshold of log2 fold change >1.2 was 
incorporated. For Biocarta, KEGG and Reactome analyses, the conservative EASE score, a 
modified Fisher exact test, was used for statistical analyses. The EASE score conservatively 
estimates the upper bound of probability using a delete-1 observation jackknife, and is 
therefore higher than standard p values.88
Gene expression data in 404 GBM and 590 ovarian cancer samples were obtained from The 
Cancer Genome Atlas data portal 5,60. Data were imported into Partek, RMA-normalized 
and log-transformed. Samples were categorized dichotomously as low or normal/high FAT1 
expressors based on probe ID 201579_at(FAT1), with low expressors defined as the lowest 
normalized quartile. ANOVA followed by false discovery correction was used to identify 
genes that were differentially expressed (FDR q<0.05; absolute log2 fold change > 1.2) 
between groups. FAT1, as the classifier, was not included in the gene list. Differentially 
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expressed genes were imported into Ingenuity Pathway Analysis to assess over-
representation of functional categories.
Clinical and microarray data in the 590 ovarian cancer samples, and in 297 glioma samples 
in the NCI Rembrandt dataset were used to identify low and normal/high FAT1 expressing 
tumors, with matched clinical outcome data. Low FAT1 expressors were defined as samples 
in the lowest normalized expression quartile. Cox multivariable regression analysis was 
performed to compare survival of patients with low FAT1 expressing tumors, compared to 
other patients, controlling for other clinicopathologic variables significant on univariate 
analysis (histology, performance status and ethnicity in glioma patients). Survival data were 
expressed as the hazard ratio for death in the low FAT1 expressing group. Mutation and 
copy number data were available for the ovarian tumors, allowing survival analysis of 
tumors with FAT1 mutation or homozygous deletion (GISTIC score of -2). These analysis 
was performed using IBM SPSS 19 and the MSKCC Computational Biology Cancer 
Genomics Portal.
The functional consequences of FAT1 mutations were predicted using Polyphen-2 version 
2.2.2, an algorithm that uses protein sequence data, structural data, and multiple alignments 
of vertebrate genomes as detailed in Supplementary Table 341.
PCR amplification and sequencing
Standard Sanger methodology was used for sequencing. Exonic regions for the genes (NCBI 
Human Genome Build 36.1) were broken into amplicons of maximum 1000bp, and specific 
primers with M13 tails were designed using Primer3 (Supplementary Table 9). PCR 
reactions were carried out in 384-well plates in a Duncan DT24 thermal cycler with 10 ng of 
whole-genome amplified DNA (REPLIg, Qiagen) as a template, using a touchdown PCR 
protocol with KAPA Fast HotStart (Kapa Biosystems). The touchdown PCR method 
consisted of: 95 °C for 5 min; 3 cycles 95 °C for 30 s, 64 °C for 15 s, 72 °C for 30 s; 3 
cycles 95 °C for 30 s, 62 °C for 15 s, 72 °C for 30 s; 3 cycles 95 °C for 30 s, 60 °C for 15 s, 
72 °C for 30 s; 37 cycles 95 °C for 30 s, 58 °C for 15 s, 72 °C for 30 s; 70 °C for 5 min. 
Templates were purified using AMPure, and sequenced bidirectionally with M13 forward/
reverse primers and the Big Dye Terminator Kit v.3.1 (Applied Biosystems) at Agencourt 
Biosciences. Dye terminators were removed using CleanSEQ (Agencourt Biosciences), and 
sequence reactions were run on ABI PRISM 3730xl (Applied Biosystems).
Mutation detection
Passing reads were assembled against the gene reference sequence, using command line 
Consed 16.089. Assemblies were passed to Polyphred 6.02b90, which generated a list of 
putative candidate mutations, and to Polyscan 3.091, which generated a second list of 
putative mutations. Outputs were merged, mutation calls normalized to ‘+ ’ genomic 
coordinates and annotated using the genomic mutation consequence calculator92. A Postgres 
database was used to annotate each mutation call (assembly position, coverage and methods 
supporting mutation call). To reduce false positives, only point mutations supported by at 
least one bidirectional read pair and at least one sample mutation called by Polyphred were 
considered, and only the putative mutations annotated as nonsynonymous, within 11bp of an 
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exon boundary, or with conservation score >0.699, were included. Single nucleotide 
polymorphisms were identified and filtered out using dbSNP (NCBI) and referencing 
sequencing data from matched normal DNA. All putative mutations were manually 
reviewed, and indels were included in the candidate list if found to hit an exon. All putative 
mutations were confirmed by a second PCR and sequencing reaction in tumor and matching 
normal DNA, to confirm all mutations were somatic.
Cloning and site-directed mutagenesis
Expression of FAT1 was accomplished by cloning a gene comprised of the N-terminus, first 
2 cadherin repeats, all 5 EGF repeats, the transmembrane region and the cytoplasmic tail, 
into the vector pcDNA 3.1. A Flag tag was added to the C-terminus. This was named 
FAT1_Trunc. Mutations identified in cancer were engineered into the constructs using 
QuikChange II XL (Stratagene). We created a non-adhesive FAT1 chimeric construct, 
fusing the IL2 receptor extracellular and transmembrane regions to the intracytoplasmic tail 
of FAT1, annotating this IL2R-FAT1_IC. IL2R protein was cloned as an additional control. 
Constructs were verified by Sanger sequencing.
Cell culture, soft agar assay, growth curve, colony formation assay
Cell lines were obtained from American Type Culture Collection and cultured using the 
recommended media (Invitrogen) + 10% FBS (Invitrogen) and penicillin/streptomycin at 37 
°C in 5% CO2. Specifically, Dulbecco Modified Eagle Medium was used to culture SNB19, 
HS683, U87, U251, IHA, and 293T; Roswell Park Memorial Institute 1640 medium, SF295; 
F-12 with proline, Chinese Hamster Ovary cells. Cancer cell line DNA was extracted using 
the Qiagen Gentra Puregene Cell Kit.
Functional assays were performed in cell lines as specified. Assays involving 
overexpression of FAT1 plasmids, were performed in cell lines with low/intermediate 
endogenous FAT1 expression: colony formation assays were performed in SF295, SNB19 
and U87 glioma cells; Subsequent assays of cell growth were performed in SF295, SNB19 
and HS683 cell lines, due to more efficient plasmid transfection in HS683. FAT1 
knockdown experiments were performed in cell lines with intermediate/high endogenous 
FAT1 expression: U87, HS683, SF295, and IHA. Experiments requiring co-transfection of 2 
or more plasmids and/or siRNAs, were performed in cell lines with high transfection 
efficiency. Specifically, SF295 cells were chosen for experiments involving synchronous 
knockdown of endogenous FAT1, and expression of FAT1_Trunc, due to high transfection 
efficiency and intermediate levels of FAT1 expression. 293T cells were chosen for 
luciferase reporter assays involving co-transfection of FAT1, β-catenin, and reporter 
plasmids, because of transfection efficiency and low baseline level of catenin-related 
transcription. Chinese Hamster Ovary cells were chosen for co-transfection of FAT1 and β-
catenin plasmids, because of transfection efficiency in similar co-transfection experiments 
with other cadherin proteins32. U251 cells were chosen for assays involving co-transfection 
of siRNAs targeting FAT1 and β-catenin; and U251 and SF295, for luciferase reporter 
assays requiring co-transfection of plasmids and siRNAs, because of transfection efficiency 
and intermediate/high endogenous FAT1 expression. Transfection was performed using 
Lipofectamine (Invitrogen) and media changed at 6 hours. Stable clones were selected using 
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G418. Cells in soft agarose assays were quantified and measured using ImageJ software 
(Research Services Branch, National Institutes of Health). Growth curve assays were 
performed in triplicate, and quantified using the Vi-Cell XR Cell Viability Analyzer 
(Beckman Coulter), or in real time, in quadruplicate, with the xCELLigence System (Roche 
Applied Science), which detects as few as 100 cells/well. xCELLigence plates were seeded 
with 5000 and 10000 cells per well, and growth reported as Cell Index, a dimensionless, 
relative measure of impedance reflecting viable, adherent cells, with a consistent, 
logarithmic relationship to cell number.
For the microarray experiment, FAT1 was knocked down using 2 siRNAs (see below, 
“siRNA knockdown of FAT1”) in duplicate, in IHA, U87 and U251 cells, and RNA 
extracted after 48 hours with Trizol (Invitrogen). RNA quality was determined with the 
Agilent 2100 Bioanalyzer.
Immunoprecipitation and immunohistochemistry
For the endogenous immunoprecipitation assay, cell lysates were incubated with antibodies 
(40 μl of anti-beta Catenin, BD Transduction Laboratories; 35 ul of anti-FAT1, Sigma; or 
3.3 ul mouse IgG as negative control, Invitrogen) and precipitated by using protein A- 
Sepharose beads that had been blocked with 3% powdered milk. For Flag-tagged transfected 
plasmids, EZview Red ANTI-FLAG M2 Affinity Gel (Sigma) was used. Beads were 
washed four times with lysis buffer and then mixed with 2× Laemmli sample buffer.
Immunohistochemistry was performed in IHA and U251 cells. Cells cultured on chamber 
slides (Thermo Fisher Scientific) were fixed by 3.7% paraformaldehyde (PFA) at room 
temperature for 10 minutes. Slides were blocked with 1% BSA in PBST (PBS + 0.3% Triton 
X-100) and then incubated with anti-β-catenin (1:200, mouse IgG, BD Biosciences), anti-
FLAG (1:500, Rabbit, Sigma-Aldrich) antibodies overnight at 4°C. After primary antibody 
incubation, slides were washed with PBST three times following incubation with secondary 
antibodies (1: 500) at room temperature for 1 hour. After wash, slides were dehydrated and 
mounted with DAPI-containing Prolong Gold antifade mounting fluid (Invitrogen). Images 
were acquired on Leica TCS SP2 confocal microscopy, and nuclear staining pixel intensity 
measured in ImageJ.
SiRNA knockdown and plasmid transfection
FAT1 siRNAs were obtained from Qiagen and Ambion. β-catenin siRNAs were obtained 
from Santa Cruz Biotechnology and Dharmacon (Supplementary Table 9). siRNAs were 
transfected in antibiotic-free media using Lipofectamine RNAiMAX (Invitrogen), media 
changed at 18-24 hours, and cells harvested at 48 hours. Cells undergoing both FAT1 
knockdown and FAT1_Trunc transfection were first transfected with siRNAs, then with 
plasmids after 18 hours, in serum and antibiotic-free media, and harvested after 48 hours.
Flow cytometry
Cells were trypsinized, fixed and stained using the standard propidium iodide method 48 h 
after transfection. Cell cycle analysis was performed on stained cells using a MoFlo cell 
sorter (Cytomation).
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β-catenin-mediated transcription (TOPFLASH) assay
For FAT1 expression, 293T cells were transfected using FuGene (Roche) with β-catenin, 
FAT constructs, or control expression constructs, the β-galactosidasegene, along with either 
TCF wildtype (Topflash) or mutated control (Fopflash) luciferase reporter plasmids. For 
FAT1 knockdown, siRNAs were transfected along with the β-galactosidase gene and 
Topflash or Fopflash plasmids, in IHA, U251 and SF295 cells, which express endogenous 
FAT1. Cells were harvested in luciferase assay buffer. Luciferase and β-galactosidase 
activities were measured (Luciferase assay system, Promega; Aurora Gal-XE 
chemiluminescent β-Galactosidase reporter, MP Biomedicals) on a Microplate luminometer 
(Turner Biosystems). Data were normalized by sample-specific β-galactosidase activity, and 
expressed as Topflash/Fopflash ratios. Experiments were performed in quintupilicate.
Mouse xenograft studies and immunohistochemistry
1 × 106 stably FAT1-transfected SNB19 cells suspended in 50% Matrigel were injected into 
the flanks of severe combined immunodeficiency mice. Growth was measured with calipers. 
26 mice were injected and 8-16 tumors were assessed for each of 5 conditions (empty 
pCDNA 3.1 vector, FAT1_Trunc, and mutants FAT1 Pro4309Ala, FAT1 Ala4419Ser, 
FAT1 Thr4511Ile). Mice were sacrificed and tumors harvested at 19 weeks. 
Immunohistochemistry for Ki-67 was performed (Vector Laboratories #VP-K451). 
Photomicrographs were taken with a Nikon Digital Sight DS-Fi1 camera on a Nikon Eclipse 
TE200-E microscope.
Fluorescence-based cell-cell adhesion assay
U87 and U251 cells, which express endogenous FAT1, were transfected with FAT1 siRNA 
as described above. SNB19 cells, which do not express endogenous FAT1, were transfected 
with pcDNA 3.1 empty vector, FAT1_Trunc, IL2R, and IL2R-FAT1_IC as described above. 
Forty-eight hours post transfection, 1 × 1010 cells/mL were resuspended in serum-free media 
+ 5uM calcein AM and incubated at 37°C for 30 minutes. Cells were washed twice with 
serum-free media and 1 × 105 cells were added to microplate wells containing confluent 
(unlabeled) cells. Calcein-labeled cells were allowed to adhere for 45 minutes at 37°C. 
Nonadherent calcein-labeled cells were washed away with media, and PBS added to each 
well. Fluorescence was measured at an absorbance of 494 nm and emission of 517 nm using 
a SpectraMax M5 Multilabel Microplate Reader (Molecular Devices). Images were taken 
using a Nikkon Eclipse TE2000E microscope (Nikon), NIS Elements AR 3.2 software and 
Photometrics CoolSnap HQ2 camera.
Antibodies
Antibodies used included FLAG (Sigma #F7425), FAT1 (Sigma #hpa023882), β-catenin 
(BD #610154 and Cell Signaling #9587s), actin (Sigma #A2066), c-myc (Cell Signaling 
#9402s), cyclin D (Cell Signaling #2922), TCF8 (Cell Signaling #3396s), ITF2 (Cell 
Signaling #2569), Claudin (Cell Signaling #4933), Id2 (Santa Cruz #sc-489), EGFR D38B1 
(Cell Signaling #8839), GLAST (Miltenyi Biotec #130-095-821), GFAP (BD Biosciences 
#561483), and Ki-67 (Vector #VP-K451).
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Statistical analysis
Two-tailed t-test, one-way ANOVA with posthoc Tukey comparisons, chi-squared, 
Wilcoxon, log-rank and Cox regression analyses were performed in GraphPad Prism or 
SPSS 19 software, with a priori level of alpha <.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The FAT1 gene is deleted and mutated at a high prevalence across multiple human 
cancers, and FAT1 suppresses cancer cell growth and proliferation
(a) Array CGH segmentation map showing select tumors with FAT1 deletions in the 
Tumorscape dataset (genomic coordinates at top). FAT1 and surrounding genes are 
indicated at bottom with blue arrows. Lower right, color legend showing copy number 
status.
(b) FAT1 copy number assayed via quantitative polymerase chain reaction in reference 
normal (red) and 42 glioblastoma samples (grey), demonstrating homozygous deletions in 
24. Error bars represent 1 standard deviation. Red asterisks indicate tumors with FAT1 
mutations. All assays performed in triplicate.
(c) Schematic of FAT1 is shown with locations of mutations. Arrowheads indicate the 
location of point mutations and boxes represent functional domains (TM, transmembrane; 
LAMG, laminin G domain; EGFCA, epidermal growth factor-like repeat; *, stop codon; fs, 
frameshift). Red arrows denote frameshift or truncating mutations. Red lines indicate 
putative β-catenin binding regions46.
(d) Colony-formation assays in indicated glioma cell lines demonstrate significant reduction 
in colony number when cells are transfected with FAT1_Trunc. Experiments performed in 
quadruplicate, colony number normalized to empty vector (pcDNA) = 1.0.
(e) Cell cycle analyses (left) demonstrate a significant reduction in S phase cells, in cells 
transfected with FAT1. BrdU assays (right) show a reduction in DNA synthesis in cells 
transfected with FAT1. Cell lines indicated. Experiments performed in triplicate. Error bars 
represent 1 standard deviation.
*p<.05, **p<.01, ***p<.001, t-test and ANOVA.
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Figure 2. The growth suppressive properties of FAT1 are abrogated by mutations observed in 
cancer
(a) Western blot of stable FAT1-expressing SNB19 GBM cells (above). Growth curve 
(below) demonstrating suppression of growth by non-mutated FAT1, but not by 
mutatedFAT1. Error bars represent 1 standard deviation.
(b) Soft agar assay of SNB19 cells stably transfected with empty vector, non-mutated FAT1, 
or mutated FAT1, demonstrating significant suppression of anchorage-independent growth 
in cells transfected with FAT1, but not when transfected with empty vector or mutated 
FAT1.
(c) BrdU assay and (d) Cell cycle assays in stable FAT1-transfected SNB19 GBM cells 
demonstrate that the anti-proliferative effect of FAT1 is compromised by FAT1 mutations. 
Error bars represent 1 standard deviation.
(e) Xenograft assay growth curve (above) shows reduction in tumor growth in stable FAT1-
transfected SNB19 cells, but not in mutated FAT1-transfected cells. Tumor incidence 
(below) at time of sacrifice at week 19 shows lowest tumor incidence in FAT1-transfected 
xenografts, compared to empty vector or mutated FAT1.
(f) Representative photographs of xenografts (week 19) demonstrates significant growth 
suppression in FAT1-transfected cells, but not in mutated FAT1-transfected cells.
(g) Representative photomicrographs of xenografts. Hematoxylin and eosin-stained sections 
at 4× power (top row) confirm invasive cancer in all xenografts. Immunohistochemistry for 
the proliferation marker Ki-67 at 4× power (middle row), and 20× power (bottom row) 
demonstrate marked suppression of cellular proliferation in FAT1-transfected cells, not seen 
with mutated FAT1. Scale bars represent 500μm (top, middle rows) and 100μm (bottom 
row).
*p<.05, **p<.01, ***p<.001, ns, non-significant, t-test and ANOVA.
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Figure 3. FAT1 inactivation results in increased cancer cell growth and proliferation
(a) Western Blots demonstrating knockdown of FAT1 expression with 2 siRNAs in the 
indicated cells. “Scramble” is non-targeting siRNA.
(b) Cell growth curves demonstrating increased growth with FAT1 knockdown, in indicated 
cells. Experiments performed in triplicate.
(c) Cell cycle analysis reveals increased number of cells entering S phase after FAT1 
knockdown. Indicated cell lines were either treated with one of 2 FAT1 siRNAs or 
scrambled siRNA control, in triplicate.
(d) BrdU incorporation assays reveal increased DNA synthesis after FAT1 knockdown. 
Experiments performed in triplicate. Error bars represent 1 standard deviation.
(e) Western blot demonstrating concomitant FAT1 knockdown with siRNA, and 
FAT1_Trunc construct transfection, in SF295 cells. Antibodies indicated.
(f) Growth curve demonstrating accelerated growth after FAT1 knockdown, partially 
reversed with concomitant transfection of FAT1_Trunc, in SF295 cells. Error bars represent 
1 standard deviation. Experiments performed in quadruplicate. Cells were plated for 
xCELLigence growth curve 24 hours after transfection, and data shown at the start of cell 
proliferation (see Methods).
(g) BrdU incorporation assay reveals increased DNA synthesis after FAT1 knockdown, 
reversed after concurrent FAT1_Trunc overexpression. Experiments performed in triplicate. 
Error bars represent 1 standard deviation.
*p<.05, **p<.01, ***p<.001, Fisher's exact test and one-way ANOVA.
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Figure 4. FAT1 is a β-catenin binding partner, inactivation of which causes aberrant Wnt 
pathway activation, translocation of β-catenin to the nucleus, and enhanced β-catenin-mediated 
transcription
(a) Immunoprecipitation assays in indicated FAT1-expressing cell lines demonstrate that 
endogenous FAT1 binds endogenous β-catenin (top), and vice versa (middle). Antibody or 
IgG negative control as indicated.
(b) Immunoprecipitation assays demonstrate binding of transfected FAT1_Trunc to 
endogenous β-catenin.
(c) Immunoprecipitation of FLAG-tagged FAT1 constructs show loss of β-catenin binding 
in mutated FAT1.
(d) Translocation of β-catenin to the nucleus after FAT1 knockdown in GBM cells and 
immortalized human astrocytes (IHA). Cells were treated with indicated siRNAs; 48 hours 
later, cells were stained with DAPI (blue) and antibody against β-catenin (green). 
Representative photos from 3 independent repeat experiments, at lower and higher 
magnification. White arrows denote plasma membrane localization; red arrows, nuclear/
perinuclear localization. Scale barsrepresent 50 μm.
(e) Quantification of results from (d). Nuclear staining expressed as pixel intensity, 
demonstrating increased nuclear localization of β-catenin after FAT1 knockdown.
(f) TOPFLASH reporter assay demonstrates reduction in β-catenin-dependent transcription 
following expression of non-mutated FAT1, but not FAT1 mutant constructs, in 293T cells. 
Reporter assays were performed as previously described52, and luciferase activity reported 
as relative fluorescence units for TOPFLASH, divided by fluorescence activity for the 
control (FOPFLASH). Error bars represent 1 standard deviation.
(g) Luciferase assay shows substantially increased β-catenin-mediated transcription after 
transfection with constitutively active β-catenin S33Y mutant, repressed with co-transfection 
of FAT1.
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*p<.05, **p<.01, ***p<.001, t-test and ANOVA.
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Figure 5. Functional relationship between β-catenin and FAT1 in the regulation of proliferation
(a) Western blot showing co-transfection of β-catenin and FAT1 in chinese hamster ovary 
(CHO) cells.
(b) Growth curve demonstrating accelerated cell growth with over-expression of β-catenin, 
repressed with co-transfection with FAT1. Error bars represent 1 standard deviation. 
Experiments performed in CHO cells, in quadruplicate.
(c) BrdU (left) and cell cycle (right) assays demonstrate enhancement in DNA synthesis and 
cells entering S phase, after β-catenin over-expression, repressed with FAT1 co-transfection. 
Experiments performed in CHO cells, in triplicate.
(d) Western blot showing co-transfection of siRNAs targeting FAT1 and β-catenin, in U251 
glioma cells.
(e) Growth curve demonstrating accelerated growth after FAT1 knockdown, reversed by 
concurrent knockdown of β-catenin. Error bars represent 1 standard deviation. Experiments 
performed in quadruplicate, in U251 glioma cells.
(f) BrdU (left) and cell cycle (right) assays demonstrate enhancement in DNA synthesis and 
cells entering S phase, after FAT1 knockdown, repressed with concurrent β-catenin 
knockdown, in U251 glioma cells. Experiments performed in triplicate. These data are 
shown with a 2nd set of siRNAs in Supplementary Fig. 3.
*p<.05, **p<.01, ***p<.001 ANOVA.
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Figure 6. Effects on Wnt/β-catenin signaling after FAT1 inactivation
(a) Western blots (below) demonstrate knockdown of FAT1 with 2 siRNAs, in the indicated 
immortalized astrocyte (IHA) and glioma cell lines. TOPFLASH luciferase reporter assay 
demonstrates increased β-catenin-dependent transcription following knockdown of FAT1 
(above). Error bars represent 1 standard deviation. *p<.05, **p<.01, ANOVA.
(b) Western blot showing upregulation of multiple Wnt targets (but not β-catenin) after 
FAT1 knockdown.
(c) Pathway analyses performed on 1539 genes differentially expressed across all cell lines 
and FAT1 siRNAs demonstrate significant enrichment of Wnt/β-catenin signaling across 
four independent pathway analysis modules. P values calculated using the Fisher test 
(Ingenuity), or the EASE score (Biocarta, KEGG, Reactome), are conservative estimates, 
depicted by log scale (–log10 p-value). Hypergeometric distribution values are p=.00009 
(Ingenuity), p=.0039 (Biocarta), p=.0007 (Reactome), and p=.015 (KEGG).
(d) Dichotomous categorization of 404 GBMs as low (lowest quartile; purple) or normal 
FAT1 expressors (left), identified 1035 differentially expressed genes. Enrichment of Wnt/β-
catenin-associated genes in low FAT1 expressors was demonstrated by Ingenuity Pathway 
Analysis (right).
(e) Of the 4 expression-defined subtypes of glioblastoma, low FAT1-expressing tumors 
were most prevalent in the Neural and Mesenchymal groups, and less common than 
expected in the Classical group (p=.0033).
(f) Dichotomous categorization of 590 ovarian cancers as low (lowest quartile) or normal 
FAT1 expressors (left), identified 189 differentially expressed genes. Pathway enrichment 
demonstrated by Ingenuity Pathway Analysis (right).
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(g) Glioma and ovarian cancer patients with low FAT1 expressing tumors experienced 
longer survival in the NCI Rembrandt glioma and TCGA ovarian cancer datasets.
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